INTRODUCTION:

Sublingual antihypertensive medicine refers to a drug that is put under the tongue in an effort to treat hypertension, which is high blood pressure. The high permeability of the fate of the sublingual area is used and this mode of administration allows the drug to be quickly assimilated into the circulation by passing through the blood capillaries in that area. One of the advantages that can be mentioned when it comes to this route includes the possibility of minimizing the rate at which the drug passes through the first pass metabolism in the liver; this is important since this may significantly boost the rate of bioavailability of the drug and thereby its effectiveness.^1-3

It is also very useful for the patients who require the treatment from hypertensive crises from the onset as this method ensures a quicker onset of medication in comparison with the oral administration. Additionally, antihypertensive medications classified under sublingual drugs include the easy to take, containing minimal side effects.Figure 01 graphical representation of Valsartan(Antihypertensive) Sublingual Formulation^4-9.

Figure 1: Graphical Representation of Valsartan Sublingual Formulation

Sublingual antihypertensive drugs and oral antihypertensive medications differ in several key aspects, particularly in terms of their administration, onset of action, and bioavailability^10-13:

Administration and Absorption:

· Sublingual Medications: These are administered sublingually and remain under the tongue where they become soluble and pass through the mucous membrane into the blood circuits. Compared to other GI-route drug delivery systems, this one can to a great extent avoid first-pass metabolism in the liver.

· Oral Medications: These are swallowed and gets assimilated through the gastrointestinal system. They get metabolized first pass in the liver this may decrease the proportion of active form of the drug that can get to the system circulation1.

Onset of Action:

· Sublingual Medications: This is because they directly affect the concentration of a drug in the blood circulation system indicating that they often have faster onset of action. This gives them more leverage in conditions where there’s need for a sharp decrease in blood pressure for instance in hypertensive emergencies.

· Oral Medications: They usually tend to have a slower rate of action because first the drug has to pass through the gastrointestinal tract before being absorbed into the bloodstream.

Bioavailability:

· Sublingual Medications: It has higher oral bioavailability since it avoids the first-pass metabolism in the liver whereby only a smaller amount of the drug reaches the systemic circulation as most is metabolized in the liver.

· Oral Medications: He said a low bioavailability can be obtained when a large proportion of the drug is metabolised in the first pass.

Convenience and Use:

· Sublingual Medications: These are commonly employed in the conditions, which require immediate intervention or management of the patient. However, due to the necessity to apply dissolvable strips accurately under the tongue, they may not be as comfortable in the long run for daily use.

· Oral Medications: These are more preferable when the disease is stable and is expected to be managed in the long-term since the tendency is that patient will benefit from continuous use of the medicine

Quality by Design approach – Antihypertensive Sublingual tablet development approach:

The Quality by Design (QbD) approach revolutionizes the way we develop antihypertensive sublingual tablets by embedding quality into every step of the process. This systematic methodology ensures that these medications are not only effective and safe but also convenient and appealing to patients.

Starting with a clear Quality Target Product Profile (QTPP) is essential. For sublingual tablets aimed at controlling high blood pressure, this profile outlines key characteristics such as rapid onset of action, precise and consistent dosing, minimal side effects, ease of administration, and long-term stability. The tablets should dissolve quickly under the tongue to provide fast relief, deliver the correct dose every time to manage blood pressure accurately, and maintain their effectiveness and safety throughout their shelf life.^14-19

Identifying Critical Quality Attributes (CQAs) follows, focusing on properties that must be controlled to meet the QTPP. For antihypertensive sublingual tablets, these attributes include the disintegration time, which should be quick to ensure rapid drug release; the dissolution rate, which should be high to facilitate swift absorption; and content uniformity, ensuring each tablet contains the right amount of active ingredient. Mechanical strength is also crucial to ensure the tablets can withstand handling without breaking, while bioavailability must be optimized to ensure the drug is effectively absorbed into the bloodstream.

A thorough risk assessment is then conducted to identify factors that could impact these CQAs. This includes evaluating the drug's properties—such as its solubility, stability, and how easily it can be absorbed through the mucosa. Understanding how the drug interacts with various excipients is also crucial, as these substances can influence the drug’s stability, how quickly it disintegrates, and its overall taste. Moreover, assessing the manufacturing processes is vital to pinpoint any potential issues that could affect the uniformity or quality of the tablets.

Designing the formulation and manufacturing processes comes next. This involves carefully selecting excipients that enhance the tablet’s performance, like super disintegrants that help the tablet dissolve quickly and sweeteners that make it taste better. Balancing these components is key to achieving the desired disintegration and dissolution rates. Developing robust manufacturing processes ensures that each tablet is made consistently, from mixing the ingredients to compressing the tablets.

Process Analytical Technology (PAT) tools play a crucial role in monitoring and controlling these processes in real time. These technologies, like in-line sensors that measure particle size and moisture, ensure that the manufacturing process remains within specified parameters, reducing the need for extensive post-production testing. Tools like Near-Infrared Spectroscopy (NIR) help maintain blend uniformity, ensuring each batch of tablets meets the quality standards set during development.

Finally, the QbD approach emphasizes continuous monitoring and improvement. After the product is on the market, it’s essential to keep testing it regularly to ensure it still meets the CQAs and QTPP. Feedback from quality checks and patient experiences helps identify areas for improvement, allowing the formulation and processes to be refined over time. This ongoing process ensures that the tablets remain effective, safe, and user-friendly throughout their lifecycle, adapting to any new regulatory requirements or scientific insights that emerge.^20-27

Development of Sublingual Formulation:

The development of sublingual formulations requires a multifaceted approach to ensure their effectiveness, safety, and patient compliance. Critical aspects to consider include the following:

Firstly, drug selection is pivotal; drugs chosen for sublingual administration must possess suitable physicochemical properties conducive to rapid absorption through the oral mucosa. This route is most effective for drugs that can be quickly absorbed in this manner. Secondly, the dosage formulation must be designed to facilitate rapid disintegration and dissolution under the tongue. Sublingual tablets are engineered to break down swiftly in the presence of saliva, enhancing the drug's absorption.

Excipient selection is another crucial factor, where components like disintegrants, binders, and sweeteners are chosen to improve the stability and bioavailability of the drug. Ensuring dose precision is equally important; sublingual tablets must consistently deliver an accurate and reliable dose to maintain their safety and efficacy.

To maximize drug absorption, bioavailability enhancement strategies, such as the use of permeation enhancers, are often employed. Given the exposure of the sublingual route to the drug’s taste, taste-masking techniques—using flavouring agents or encapsulation technologies—are essential to improve patient acceptability.

Stability studies are conducted to assess the physicochemical stability of the sublingual tablets over time, which is critical for determining the product's shelf life and appropriate storage conditions. Additionally, developing a manufacturing process that ensures uniformity and consistency in tablet production is necessary, often involving methods like direct compression or granulation.

Robust quality control measures are implemented to monitor the critical attributes of sublingual tablets, such as disintegration time, dissolution rate, and content uniformity. Ensuring regulatory compliance is also vital; pharmaceutical products must meet the standards set by health authorities, necessitating thorough documentation and approval.

Finally, patient compliance is a key consideration. The ease of use and acceptability of sublingual tablets are crucial for encouraging adherence to the prescribed regimen. Formulating sublingual tablets to be user-friendly is essential for improving patient adherence and overall treatment success^28-33.

Preformulation parameters of Sublingual Formulation”

Developing sublingual formulations involves understanding several crucial preformulation parameters.³⁴

Preformulation Results of Valsartan (Antihypertensive Medication)

Results of melting point

S. No	Melting point of Valsartan (°C)
Average	116-117 °C

Results of determination of λ max in methanol

S. No	λ max
1	250 nm

UV Spectrum scanning for Valsartan

Valsartan calibration data in UV spectrophotometer

Solvent	Concentration (µg/mL)	Absorbance (nm)
1	0	0.2047
2	2	0.3063
3	4	0.4454
4	6	0.5281
5	8	0.6736
6	10	0.7537
7	12	0.8654

Valsartan calibration Curve

Fourier Transform Infra-Red (FT-IR) spectroscopy

Results of Valsartan FTIR

Results of Sodium Starch Glycolate FTIR

Results of Crospovidone FTIR

Results of Microcrystalline cellulose FTIR

Results of Croscarmellose FTIR

Evaluating of Sublingual Formulation:

Evaluating sublingual formulations is a comprehensive process that ensures their effectiveness, safety, and user-friendliness. Key parameters include:³⁵

Disintegration Time is crucial; it measures how quickly the sublingual tablet breaks down under the tongue. Rapid disintegration is essential for swift drug release and absorption through the mucosa. Closely related is the Dissolution Rate, which gauges how fast the drug dissolves in saliva once disintegration occurs. A higher dissolution rate is vital for making the drug available for absorption quickly, thereby enhancing its bioavailability and therapeutic effectiveness.

Content Uniformity is another important factor, ensuring that each tablet consistently delivers the same amount of active drug. This consistency is critical for maintaining the drug’s safety and effectiveness. The Bioavailability of the drug, or the extent to which it reaches the systemic circulation, is a direct measure of the drug's efficacy. High bioavailability indicates efficient drug absorption through the sublingual route.

Taste and Palatability are significant for patient compliance, as the sublingual administration directly exposes the drug's taste to the patient. Poor taste can deter usage, so formulations often employ taste-masking techniques to improve the flavour profile.

The Mechanical Strength of the tablets is also evaluated to ensure they are robust enough to withstand handling and transportation without crumbling or breaking apart. This characteristic is essential for maintaining the integrity of the dosage form until use.

Stability is a key parameter that assesses the formulation’s ability to maintain its physical, chemical, and microbiological integrity over time. Stability studies help determine the product's shelf life and suitable storage conditions.

Mucosal Irritation Potential is assessed to ensure the sublingual tablet does not cause discomfort or harm to the oral mucosa. This evaluation is critical to avoid adverse reactions that could discourage patient adherence.

The Onset of Action is particularly important for sublingual formulations, which are often used for rapid relief. This parameter measures how quickly the drug begins to exert its therapeutic effect after administration.

Manufacturability pertains to the feasibility of producing the sublingual tablets on a commercial scale. This involves evaluating the consistency and cost-effectiveness of the production process while maintaining the quality of the product.

Finally, Patient Compliance is a critical factor in the overall success of the formulation. Factors such as ease of use, taste, and convenience significantly influence whether patients adhere to their prescribed treatment regimen.

Together, these evaluation parameters ensure that sublingual formulations are not only effective and safe but also acceptable and convenient for patients.

CONCLUSIONS:

Thus, sublingual antihypertensive agents are a veritable option to the conventional oral preparations since they ensure the quick delivery system and increased blood solubility due to the support of the first-pass metabolism in the liver. of course, this line of treatment has significant benefit in dealing with hypertensive emergency situations and for client who needs an immediately aggressive treatment. Thus, all related processes starting from the selection of the drug up to its manufacturing is designed to be fully effective, safe, and compliance with the patient’s needs, which is achieved with the help of QbD approach. The development and evaluation of the compounds focus on the properties like solubility, permeability and stability and also on the considerations that includes taste and ease of administration. In fact, sublingual formulations such as those for Valsartan signify a breakthrough in hypertensive management as patients can experience quicker and more effective relief of their symptoms while tending to the form and shape of the product.

ABBREVIATIONS:

QbD: Quality by Design; QbT: Quality by Testing; CMAs: critical material attributes; CPPs: critical process parameters; QTPP: quality target product profile; DS: design space; DoE: design of experiments; API: Active Pharmaceutical Ingredient; CQAs: critical quality attributes

REFERENCE:

1. Singh SK, Sameer AA. Development and characterization of sublingual tablet of lisinopril. Asian Pac J Trop Biomed. 2012; S1711-S1719.

2. Vyas AS, Patel KM, Patel HM, Soni SJ, Patel DB. Formulation, development and evaluation of ramipril sublingual tablets. Int J Pharm Res Biosci. 2013; 2(2): 191-202.

3. Sramika NR, Debnath S, Niranjan Babu M. Formulation and evaluation of sublingual tablets of nimodipine. Indian Am J Pharm Res. 2013; 3(12): 1256-1261.

4. Joshi D, Choudhary NK. Enhancing sublingual tablet quality through QbD: Current trends and insights. Precis Nanomed. 2023; 6(3): 1099-1108.

5. Parmar TB, Prajapati TK, Patel CN. Formulation and evaluation of sublingual tablet of valsartan. Int J Pharm Res Biosci. 2014; 3(2): 969-989.

6. Patel RJ, Patel BN, Patel DM, Patel CN. Formulation and evaluation of felodipine sublingual tablet. World J Pharm Pharm Sci. 2014; 3(6): 850-864.

7. Chaudhari KP, Jadhao UT, Chaudhari CD, Thakare VM, Tekade BW, Chaudhari CS. Formulation and evaluation of fast dissolving sublingual tablets of amlodipine besylate. Drug Des Dev Ther. 2014; 5(4): 1-9.

8. Chinchore MV, Kothawade PD, Surwase RK, Maru AD. Formulation, optimization and evaluation of amlodipine besylate sublingual films. Res J Pharm Technol. 2014; 7(8): 840-844.

9. Verma H, Pal P, Joshi D. Formulation, development and evaluation of invasomes loaded gel for fungal treatment. Sch Acad J Pharm. 2022; 7: 105-108.

10. Srilatha G, Potnuri NR, Shivabindu K. Design and characterization of fast release sublingual tablets of atenolol. Indian J Pharm Sci Rev Res. 2014; 27(2): 231-235.

11. Patel RJ, Patel BN, Patel DM, Patel CN. Formulation and evaluation of felodipine sublingual tablet. World J Pharm Pharm Sci. 2014; 3(6): 850-864.

12. Gaikwad SS, Jadhav SS, Chavan MK, Salikhe KS, Ramteke KH, Chaudhari SR. Design and in vitro evaluation of sublingual tablet of timolol maleate. Appl Clin Res Clin Trials RegulAff. 2016; 3(1): 56-63.

13. Dandia PC, Kulkarni SK. Introduction to Pharmacology. New Delhi: Vallabh Prakashan; 2012.

14. Dave V, Haware R, Sangave N, Sayles M, Popielarczyk M. Drug-excipient compatibility studies in formulation development: Current trends and techniques. AAPS FDD Sect Newsl. 2015; Jan.

15. Desai D, Wang J, Wen H, Li XH, Timmins P. Formulation design, challenges, and development considerations for fixed dose combination (FDC) of oral solid dosage forms. Pharm Dev Technol. 2013; 18: 1265-1276. https://doi.org/10.3109/10837450.2012.660699.

16. Destro F, Barolo M. A review on the modernization of pharmaceutical development and manufacturing – Trends, perspectives, and the role of mathematical modeling. Int J Pharm. 2022; 620: 121715. https://doi.org/10.1016/j.ijpharm.2022.121715.

17. Dey S, Mahanti B, Khila S, Mazumder B, Gupta SD. Formulation development and optimization of bilayer tablets of aceclofenac. Expert Opin Drug Deliv. 2012; 9: 1041-1050. https://doi.org/10.1517/17425247.2012.707187.

18. Dholariya YN, Bansod YB, Vora RM, Mittal SS, Shirsat AE. Design and optimization of bilayered tablet of hydrochlorothiazide using the Quality-by-Design approach. Int J Pharm Investig. 2014; 4: 93-101. https://doi.org/10.4103/2230-973x.133058.

19. Ishikawa D, Genkawa T, Murayama K, Komiyama M, Ozaki Y. Feasibility study of diffuse reflectance and transmittance near infrared spectroscopy for rapid analysis of ascorbic acid concentration in bilayer tablets using a high-speed polychromator-type spectrometer. J Near Infrared Spectrosc. 2014; 22: 189-197. https://doi.org/10.1255/jnirs.1116.

20. Hagen E, Løding FS, Mattsson S, Tho I. Use of interactive mixtures to obtain mini-tablets with high dose homogeneity for paediatric drug delivery. J Drug Deliv Sci Technol. 2016; 34: 51-59. https://doi.org/10.1016/j.jddst.2016.03.006.

21. Lopes CM, Lobo JM, Pinto JF, Costa PC. Compressed matrix core tablet as a quick/slow dual-component delivery system containing ibuprofen. AAPS PharmSciTech. 2007; 8 https://doi.org/10.1208/pt0803076.

22. Van der Merwe SM, Verhoef JC, Kotze AF, Junginger HE. N-trimethyl chitosan chloride as an absorption enhancer in oral peptide drug delivery. Development and characterization of minitablet and granule formulations. Eur J Pharm Biopharm. 2004; 57: 85-91. https://doi.org/10.1016/S0939-6411(03)00152-8.

23. Bowles A, Keane J, Ernest T, Clapham D, Tuleu C. Specific aspects of gastrointestinal transit in children for drug delivery design. Int J Pharm. 2010; 395: 37-43. https://doi.org/10.1016/j.ijpharm.2010.04.048.

24. Shukla D, Chakraborty S, Singh S. Mouth dissolving tablets I: An overview of formulation technology. Sci Pharm. 2009; 77: 309-326. https://doi.org/10.3797/scipharm.0811-09-01.

25. Ritschel WA, Bauer-Brandl A. Die Tablette: Handbuch Der Entwicklung, Herstellung Und Qualitätssicherung. ECV-Editio Cantor Verlag; 2002. Retrieved from http://www.ecv.de.

26. Bauer H. Herstellung und Charakterisierung von KombinationenausMannit und SorbitdurchSprühtrocknung und Co-granulation. Doctoral dissertation, Verlag nichtermittelbar; 2000. Retrieved from https://d-nb.info/963170031/34.

27. Saha S, Shahiwala AF. Multifunctional coprocessed excipients for improved tabletting performance. Expert Opin Drug Deliv. 2009; 6: 197-208. https://doi.org/10.1517/17425240802708978.

28. Bolhuis GK, Rexwinkel EG, Zuurman K. Polyols as filler-binders for disintegrating tablets prepared by direct compaction. Drug Dev Ind Pharm. 2009; 35: 671-677. https://doi.org/10.1080/03639040802587799.

29. Charoo NA, Shamsher AA, Zidan AS, Rahman Z. Quality by design approach for formulation development: A case study of dispersible tablets. Int J Pharm. 2012; 423: 167-178. https://doi.org/10.1016/j.ijpharm.2011.12.024.

30. Sugimoto M, Matsubara K, Koida Y, Kobayashi M. The preparation of rapidly disintegrating tablets in the mouth. Pharm Dev Technol. 2001; 6: 487-493. https://doi.org/10.1081/PDT-100108065.

31. Aslan N, Cebeci Y. Application of Box–Behnken design and response surface methodology for modeling of some Turkish coals. Fuel. 2007; 86: 90-97. https://doi.org/10.1016/j.fuel.2006.06.010.

32. Beg S, Sandhu PS, Batra RS, Khurana RK, Singh B. QbD-based systematic development of novel optimized solid self-nanoemulsifying drug delivery systems (SNEDDS) of lovastatin with enhanced biopharmaceutical performance. Drug Deliv. 2015; 22(6): 765-784. https://doi.org/10.3109/10717544.2014.900154.

33. Beg S, Jain A, Kaur R, Panda SS, Katare OP, Singh B. QbD-driven development and validation of an efficient bioanalytical UPLC method for the estimation of olmesartanmedoxomil. J LiqChromatogrRelat Technol. 2016. https://doi.org/10.1080/10826076.2016.1206023.

34. Iancu V, Roncea F, Cazacincu RG, Lupuleasa D. Preparation and evaluation of diclofenac sodium orally disintegrating tablets. Ovidius Univ Ann Chem. 2016; 27: 58-61. Available from: http://anale-chimie.univ-ovidius.ro/anale-chimie/ahead-of-print2016/Article_4_v2.pdf.

35. Comoglu T, Ozyilmaz ED. Orally disintegrating tablets and orally disintegrating mini tablets – novel dosage forms for pediatric use. Pharm Dev Technol. 2019; 24: 902-914. https://doi.org/10.1080/10837450.2019.1615090.

36. Joshi D, Choudhary NK. Implementation of Quality by Design of Sublingual Antihypertensive Drugs. J Pharm Innov. 2024; 19: 20. https://doi.org/10.1007/s12247-024-09832-y.

Received on 22.02.2024 Revised on 14.05.2024

Accepted on 26.07.2024 Published on 20.01.2025

Available online from January 27, 2025

Research J. Pharmacy and Technology. 2025;18(1):245-250.

DOI: 10.52711/0974-360X.2025.00038

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License. Creative Commons License.